Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Maia Biotechnology is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies and telomere-targeting agents for cancer. Its lead candidate, THIO, aims to treat various solid tumors, including non-small cell lung cancer, by disrupting telomeres and activating immune responses. The company leverages proprietary technology, strategic collaborations, and a robust patent portfolio to advance innovative cancer treatments across multiple indications and markets.
This description was generated via AI from an annual report. Updated about 1 year ago.